Role of MicroRNAs in Parkinson's Disease

Parkinson's disease (PD) is a disabling neurodegenerative disease that manifests with resting tremor, bradykinesia, rigidity and postural instability. Since the discovery of microRNAs (miRNAs) in 1993, miRNAs have been shown to be important biological molecules involved in diverse processes to...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-11, Vol.20 (22), p.5649
Main Authors: Goh, Suh Yee, Chao, Yin Xia, Dheen, Shaikali Thameem, Tan, Eng-King, Tay, Samuel Sam-Wah
Format: Article
Language:English
Subjects:
Animals
Biomarkers
Blood
Brain research
Diagnostic systems
Disease
Dopamine
Gene expression
Gene Expression Regulation
Humans
Kinases
Leukocytes
MicroRNAs
MicroRNAs - genetics
miRNA
Parkinson Disease - genetics
Parkinson Disease - pathology
Parkinson's disease
Pathogenesis
Peripheral blood
Prefrontal cortex
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson's disease (PD) is a disabling neurodegenerative disease that manifests with resting tremor, bradykinesia, rigidity and postural instability. Since the discovery of microRNAs (miRNAs) in 1993, miRNAs have been shown to be important biological molecules involved in diverse processes to maintain normal cellular functions. Over the past decade, many studies have reported dysregulation of miRNA expressions in PD. Here, we identified 15 miRNAs from 34 reported screening studies that demonstrated dysregulation in the brain and/or neuronal models, cerebrospinal fluid (CSF) and blood. Specific miRNAs-of-interest that have been implicated in PD pathogenesis include miR-30, miR-29, let-7, miR-485 and miR-26. However, there are several challenges and limitations in drawing definitive conclusions due to the small sample size in clinical studies, varied laboratory techniques and methodologies and their incomplete penetrance of the blood-brain barrier. Developing an optimal delivery system and unravelling druggable targets of miRNAs in both experimental and human models and clinical validation of the results may pave way for novel therapeutics in PD.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20225649